/
A Danish study of 756,636 pregnancies found early exposure to semaglutide or liraglutide linked to preterm birth only in women treated for diabetes, not weight management. Researchers say diabetes may explain it, but safety remains uncertain.

A Danish registry study of more than 750,000 pregnancies has found that early exposure to semaglutide or liraglutide was linked to premature birth only in women who had been prescribed the drugs for diabetes. Women prescribed them for weight management showed no such link. The European Society of Human Reproduction and Embryology issued the findings on 13 November, from research published in the journal Human Reproduction Open.
The medicines belong to a group called GLP-1 receptor agonists. Semaglutide is sold as Ozempic and Wegovy, and liraglutide as Saxenda. They were first developed to treat type 2 diabetes, and because they also suppress appetite, they are widely used for weight loss. Their safety during pregnancy has not been established.
Professor Henriette Svarre Nielsen led the research. Her team reported that women who filled prescriptions for either drug to treat diabetes had higher adjusted odds of delivering before 37 weeks. Among women who took the same drugs for weight management, the researchers found no statistically detectable increase in preterm birth, and none in the other complications they examined.
The authors read the split as a pointer to diabetes itself, rather than the medication, as the likelier explanation for the earlier deliveries. They did not present it as proof.
The team drew on Denmark's national health registries. They reviewed 756,636 pregnancies involving a single baby, among 480,231 women, with deliveries between 2009 and 2023. Twin and other multiple pregnancies were outside the study.
Exposure was defined by pharmacy records. A pregnancy counted as potentially exposed if the woman filled a prescription for semaglutide or liraglutide in the eight weeks before or after the first day of her last menstrual period. That window can cover early pregnancy, before a woman knows she is pregnant, which is why the society described the women as having used the drugs unintentionally. The records showed possible exposure in 529 pregnancies.
The researchers looked at six outcomes: preterm birth, pre-eclampsia, gestational diabetes, delivery of a baby unusually large for its gestational age, stillbirth and placental complications. They adjusted their analyses for maternal age, body mass index, smoking, education, place of residence and existing diabetes, along with the timing of the pregnancy.
The split by reason for prescribing is the central result. In the diabetes group, higher adjusted odds of birth before 37 weeks appeared. In the weight-management group, no clear increase appeared in preterm birth or in any other complication on the list. For a woman who took one of these drugs for weight loss and then learned she was pregnant, the data are reassuring on those outcomes. They do not settle the wider question of safety.
The work is observational, and the researchers state that it cannot establish the cause of the association it found. It records who filled a prescription and what happened afterwards. It cannot show why the preterm births occurred, or rule out other differences between women with diabetes and women without it.
That limit applies in both directions. The higher odds among women treated for diabetes do not prove the drugs caused earlier delivery, and the absence of a clear increase among women treated for weight management does not prove the drugs are safe in pregnancy. The authors' reading, that diabetes may help explain the diabetes-group result, remains a suggestion drawn from the pattern in the data.
The size of the exposed group matters too. Out of more than 756,000 pregnancies, 529 were flagged as potentially exposed, so the comparisons for each reason for prescribing rest on far fewer cases than the headline total suggests. Exposure was judged from filled prescriptions in a fixed window around the start of the last menstrual period, which is a proxy for use rather than a record of every dose taken.
The society said in its release that the drugs' safety during pregnancy remains uncertain, despite the reassuring result for weight-loss prescriptions. Clinicians generally advise stopping GLP-1 drugs before planned conception.
Unplanned pregnancies are a recognised part of the picture. UT Southwestern Medical Center said in June 2024 that GLP-1 drugs have helped patients lose an average of 15% to 20% of their body weight in clinical trials, and that for people with obesity, significant weight loss can restore ovulation and regular periods. Those changes can lead to unexpected pregnancy. The centre cited a recent poll finding that one in eight adults had taken a GLP-1 drug, and said data on how the drugs affect fertility, pregnancy and breastfeeding were limited.
The Danish findings sit beside other work from the same country's health system. A separate analysis of electronic hospital records from the Central Denmark Region, covering conceptions between June 2016 and June 2023 in a cohort of more than 100,000 pregnancies, examined semaglutide exposure in the first trimester. It reported higher risks of preterm birth, large-for-gestational-age babies, neonatal low blood sugar and jaundice in semaglutide-exposed pregnancies. Its authors noted that unintentional use of semaglutide in pregnancy was increasing rapidly and that women who experienced it were hard to advise because human data were lacking.
Data collection is continuing elsewhere. The Wegovy Pregnancy Registry, which operates in the United States, gathers health information from pregnant women, including those on prescription medicines, and follows their newborns' health up to the age of one year. Pregnant women with a diagnosis of obesity or overweight may be eligible to take part whether or not they have used Wegovy. The registry takes enquiries on 1-877-390-2760, toll-free, from 8.30am to 5.00pm EST, Monday to Friday.
About the Author
Staff Writer
Prateek Rawat is a contributor to Wirony. All articles published under this byline undergo editorial review and approval before publication, with any necessary corrections handled…
What did you think?
World Mental Health Day 2026, observed on 10 October, focused on putting lived experience at the centre of mental health policy and care. Ghana reported 36,196 recorded cases across five conditions in Jan–Jun 2026, up from 29,782 a year earlier.
Prateek Rawat5 min